Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Verona Gains FDA Nod for COPD Drug, Plans Q3 Launch
FDA approved Verona Pharma's Ohtuvayre, a novel inhaled treatment for COPD, marking the first new mechanism in over 20 years. It's a dual PDE3 and PDE4 inhibitor offering bronchodilator and anti-inflammatory effects. Set for Q3 2024 launch, backed by $1 billion, with pricing yet announced. Supported by Phase III trials showing improved lung function and reduced exacerbations.
Homozygous Familial Hypercholesterolemia Market Growth Forecast and Emerging Therapies
DelveInsight's report on Homozygous Familial Hypercholesterolemia (HoFH) forecasts market growth, driven by increasing prevalence and new therapies. The 7MM saw 2,845 HoFH cases in 2022, expected to rise by 2034. Key companies like Novartis and Sanofi are developing treatments targeting LDL-C reduction, with the market valued at USD 108 million in 2022.
Verona Wins FDA Approval for COPD Drug, Eyes Q3 Launch
FDA approved Verona Pharma’s Ohtuvayre, a novel COPD treatment with a unique dual-inhibitor mechanism, marking a significant advance in COPD care. Expected to launch in Q3 2024, it improves lung function and reduces exacerbations. Verona secured up to $650M for its rollout, with pricing yet undisclosed.
CRAACO® 2024 Conference Reports on the Convergence of Clinical Research and Care
The 9th annual CRAACO® conference, focusing on integrating clinical research with care to enhance trial participation and health outcomes, will be held on September 16, 2024, in Philadelphia. It aims to unite stakeholders to improve access to clinical trials, especially in underserved areas, and discuss the convergence of clinical care and research.
EHA 2024: Monoclonal antibodies continue to dominate multiple myeloma treatments
At EHA 2024, key studies on MM treatments were presented, including DREAMM-8, LINKER-MM1, and GMMG-HD7. Blenrep showed promising results in RRMM, with a 77% ORR. Linvoseltamab demonstrated efficacy in RRMM, with a 71% ORR. Sarclisa improved treatment responses in newly diagnosed MM, showing higher MRD negativity rates.
Related Clinical Trials:
Mid-Stage Trial Failure for Sanofi and Denali's ALS Drug
Stay updated on biopharmaceutical advancements with the Synapse database, offering daily or weekly insights into drugs, targets, indications, and organizations.
Generative AI: The New Lifeline To Overwhelmed Healthcare Systems
Generative AI is emerging as a solution to healthcare's challenges, including workforce shortages and rising caseloads, by automating tasks like patient guidance, administrative work, data retrieval, and drug development. Despite its potential, the effectiveness of generative AI depends on the quality of the data it's trained on, emphasizing the need for careful data preparation.
Surprise: Eli Lilly Is Racing Toward Yet Another Blockbuster
Eli Lilly's shares have outperformed the market due to clinical and regulatory progress. Its new once-weekly insulin, efsitora alfa, shows promise for type 2 diabetes treatment, though it trails Novo Nordisk's Awiqli. Eli Lilly's strong portfolio, including Zepbound and Mounjaro, and a robust pipeline suggest continued growth, making efsitora alfa a small part of its expansion.
Kymera Therapeutics Inc (KYMR) (Q1 2024) Earnings Call Transcript Highlights
Kymera Therapeutics reported $10.3M revenue, $745M cash balance, and a financial runway into 2027. Progressing KT-474 into Phase 2 trials, it faces competition and clinical trial risks. Encouraging data presented at medical meetings, with a focus on developing effective, safe oral treatments.
Q1 2024 Exscientia PLC Earnings Call
Exscientia's Q1 2024 update highlights progress in AI-driven drug design, automation, and pipeline development, including advancements in CDK7, LSD1, and MALT1 inhibitors. The company expects to save $40M annually from 2025, extending cash runway into 2027, and emphasizes partnerships and operational efficiencies.
© Copyright 2025. All Rights Reserved by MedPath